{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:58:42Z","timestamp":1768409922838,"version":"3.49.0"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1006266","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000}}],"reference-count":77,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Amschwand Sarcoma Cancer Foundation Award"},{"name":"Welch Foundation\u2019s Robert A. Welch Distinguished University Chair Award","award":["G-0040"],"award-info":[{"award-number":["G-0040"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["R120501"],"award-info":[{"award-number":["R120501"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1006266","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T13:30:49Z","timestamp":1532439049000},"page":"e1006266","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5208-6016","authenticated-orcid":true,"given":"Chia-Chin","family":"Wu","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5078-534X","authenticated-orcid":true,"given":"Hannah C.","family":"Beird","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5412-9860","authenticated-orcid":true,"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"P. Andrew","family":"Futreal","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"N Stransky","year":"2014","journal-title":"Nat Commun"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cell.2009.04.034","article-title":"Commonality but diversity in cancer gene fusions","volume":"137","author":"TH Rabbitts","year":"2009","journal-title":"Cell"},{"issue":"8","key":"ref3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrc3087","article-title":"Advances in sarcoma genomics and new therapeutic targets","volume":"11","author":"BS Taylor","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"7489","key":"ref4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature13109","article-title":"C11orf95-RELA fusions drive oncogenic NF-\u03baB signalling in ependymoma","volume":"506","author":"M Parker","year":"2014","journal-title":"Nature"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"E Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrg3013","article-title":"Towards systematic functional characterization of cancer genomes","volume":"12","author":"JS Boehm","year":"2011","journal-title":"Nat Rev Genet"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations","volume":"7","author":"IA Adzhubei","year":"2010","journal-title":"Nat Methods"},{"issue":"18","key":"ref8","doi-asserted-by":"crossref","first-page":"i640","DOI":"10.1093\/bioinformatics\/bts402","article-title":"PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis","volume":"28","author":"S Ng","year":"2012","journal-title":"Bioinformatics"},{"issue":"9","key":"ref9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/bioinformatics\/btt131","article-title":"Identification of Cancer Fusion Drivers Using Network Fusion Centrality","volume":"29","author":"CC Wu","year":"2013","journal-title":"Bioinformatics"},{"issue":"20","key":"ref10","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/bioinformatics\/btt445","article-title":"Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions","volume":"29","author":"M Shugay","year":"2013","journal-title":"Bioinformatics"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12918-014-0097-z","article-title":"Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer","volume":"8","author":"F Abate","year":"2014","journal-title":"BMC Systems Biology"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nbt1103","article-title":"Probabilistic model of the human protein-protein interaction network","volume":"23","author":"DR Rhodes","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"e1002797","DOI":"10.1371\/journal.pcbi.1002797","article-title":"Genomic hallmarks of genes involved in chromosomal translocations in hematological cancer","volume":"8","author":"M Shugay","year":"2012","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molcel.2016.07.008","article-title":"Molecular principles of gene fusion mediated rewiring of protein interaction networks in cancer","volume":"63","author":"NS Latysheva","year":"2016","journal-title":"Mol. Cell"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.1093\/nar\/gkx423","article-title":"ChiPPI: a novel method for mapping chimeric protein-protein interactions uncovers selection principles of protein fusion events in cancer","volume":"45","author":"M Frenkel-Morgenstern","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"5618","key":"ref16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1126\/science.1083653","article-title":"Assembly of cell regulatory systems through protein interaction domains","volume":"300","author":"T Pawson","year":"2003","journal-title":"Science"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrg2918","article-title":"Network medicine: a network-based approach to human disease","volume":"12","author":"AL Barab\u00e1si","year":"2011","journal-title":"Nat Rev Genet"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ajhg.2008.02.013","article-title":"Walking the interactome for prioritization of candidate disease genes","volume":"82","author":"S K\u00f6hler","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"43","key":"ref19","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"A Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"ref20","article-title":"An algorithm for fast pre-ranked gene set enrichment analysis using cumulative statistic calculation","author":"A Sergushichev","year":"2016","journal-title":"bioRxiv"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/gepi.0042","article-title":"Truncated product method for combing p-values","volume":"22","author":"DV Zaykin","year":"2002","journal-title":"Genetic Epidemiology"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/nar\/gkg034","article-title":"STRING: a database of predicted functional associations between proteins","volume":"31","author":"C von Mering","year":"2003","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/bioinformatics\/btq044","article-title":"Prediction of Human Functional Genetic Networks from Heterogeneous Data Using RVM-Based Ensemble Learning","volume":"26","author":"CC Wu","year":"2010","journal-title":"Bioinformatics"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0145-2126(01)00197-7","article-title":"Bcr-Abl variants: biological and clinical aspects","volume":"26","author":"AS Advani","year":"2002","journal-title":"Leuk Res"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cell.2012.02.002","article-title":"Spatial organization of the mouse genome and its role in recurrent chromosomal translocations","volume":"148","author":"Y Zhang","year":"2012","journal-title":"Cell"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"D Cilloni","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1596\/neo.12230","article-title":"A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis","volume":"14","author":"X Qiu","year":"2012","journal-title":"Neoplasia"},{"issue":"56","key":"ref28","doi-asserted-by":"crossref","first-page":"8591","DOI":"10.1038\/sj.onc.1206087","article-title":"BCR\/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability","volume":"21","author":"T Skorski","year":"2012","journal-title":"Oncogene"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2011-10-383752","article-title":"Targeting hedgehog in hematologic malignancy","volume":"119","author":"DA Irvine","year":"2012","journal-title":"Blood"},{"issue":"8","key":"ref30","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"issue":"7347","key":"ref31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition","volume":"473","author":"C Duy","year":"2011","journal-title":"Nature"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT signaling maizntains survival of Ph+ leukemia cells upon inhibition of BCR-ABL","volume":"18","author":"MA Gregory","year":"2010","journal-title":"Cancer Cell"},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"S Li","year":"1999","journal-title":"J Exp Med"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nmeth.2689","article-title":"DGIdb: mining the druggable genome","volume":"10","author":"M Griffith","year":"2013","journal-title":"Nat Methods"},{"issue":"9","key":"ref35","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"P Gallipoli","year":"2014","journal-title":"Blood"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.leukres.2013.11.006","article-title":"Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia","volume":"38","author":"C Quintarelli","year":"2014","journal-title":"Leuk Res"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1634\/theoncologist.2014-0032","article-title":"Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data","volume":"19","author":"MM Kirstein","year":"2014","journal-title":"Oncologist"},{"issue":"18","key":"ref38","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1158\/0008-5472.CAN-13-1318","article-title":"KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors","volume":"73","author":"AS Corbin","year":"2013","journal-title":"Cancer Res"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"F Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/ijc.28427","article-title":"Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha","volume":"134","author":"RM El Eit","year":"2014","journal-title":"Int J Cancer"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/mol.106.033308","article-title":"The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr\/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation","volume":"72","author":"M Rahmani","year":"2007","journal-title":"Mol Pharmacol"},{"issue":"9","key":"ref42","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1158\/0008-5472.CAN-08-2978","article-title":"Sorafenib induces apoptosis specifically in cells expressing BCR\/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway","volume":"69","author":"T Kurosu","year":"2009","journal-title":"Cancer Res"},{"issue":"13","key":"ref43","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1158\/1078-0432.CCR-10-0232","article-title":"The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo","volume":"16","author":"J Paesler","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2004-07-2967","article-title":"Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance","volume":"105","author":"P.H. Tseng","year":"2005","journal-title":"Blood"},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.leukres.2007.11.007","article-title":"Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1","volume":"32","author":"KM Arunasree","year":"2008","journal-title":"Leuk Res"},{"issue":"7","key":"ref46","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/leu.2008.89","article-title":"Disruption of the Bcr-Abl\/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin","volume":"22","author":"LX Wu","year":"2008","journal-title":"Leukemia"},{"issue":"19","key":"ref47","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-08-0721","article-title":"Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells","volume":"14","author":"W Fiskus","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2013.228","article-title":"CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway","volume":"27","author":"RC Prins","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"ref49","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2012.331","article-title":"CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing","volume":"27","author":"KM Badger-Brown","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"ref50","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"H Makishima","year":"2011","journal-title":"Blood"},{"issue":"7\u20138","key":"ref51","first-page":"650","article-title":"Conditional RNAi: towards a silent gene therapy","volume":"61","author":"SK Lee","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"ref52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.semcancer.2005.01.005","article-title":"The EWS-WT1 gene fusion in desmoplastic small round cell tumor","volume":"15","author":"WL Gerald","year":"2005","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/carcin\/bgp317","article-title":"The EWS\/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin\/TCF-mediated transcription","volume":"31","author":"D Navarro","year":"2010","journal-title":"Carcinogenesis"},{"issue":"16","key":"ref54","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1128\/MCB.24.16.7275-7283.2004","article-title":"EWS\/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3","volume":"24","author":"A Prieur","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"15","key":"ref55","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/sj.onc.1206330","article-title":"Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells","volume":"22","author":"A. Uren","year":"2003","journal-title":"Oncogene"},{"issue":"7","key":"ref56","doi-asserted-by":"crossref","first-page":"e2569","DOI":"10.1371\/journal.pone.0002569","article-title":"FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C\/EBPalpha and activating eIF4E","volume":"3","author":"PA P\u00e9rez-Mancera","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"ref57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/nar\/gkt835","article-title":"PARP-1 dependent recruitment of the amyotrophic lateral sclerosis-associated protein FUS\/TLS to sites of oxidative DNA damage","volume":"42","author":"SL Rulten","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/1476-4598-9-257","article-title":"Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option","volume":"9","author":"SM Willems","year":"2010","journal-title":"Mol Cancer"},{"issue":"24","key":"ref59","doi-asserted-by":"crossref","first-page":"20215","DOI":"10.18632\/oncotarget.4046","article-title":"FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro","volume":"6","author":"H K\u00fcnstlinger","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"ref60","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccell.2014.10.004","article-title":"EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma","volume":"26","author":"N Riggi","year":"2014","journal-title":"Cancer Cell"},{"issue":"11","key":"ref61","doi-asserted-by":"crossref","first-page":"e1307","DOI":"10.1073\/pnas.1500536112","article-title":"Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing","volume":"112","author":"SP Selvanathan","year":"2015","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"ref62","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/0008-5472.CAN-15-1572","article-title":"CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1","volume":"76","author":"H Sun","year":"2016","journal-title":"Signaling. Cancer Res"},{"issue":"3","key":"ref63","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"R Macarron","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"ref64","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1158\/0008-5472.CAN-11-3648","article-title":"PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma","volume":"72","author":"JC Brenner","year":"2012","journal-title":"Cancer Res"},{"issue":"7391","key":"ref65","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"MJ Garnett","year":"2012","journal-title":"Nature"},{"issue":"3","key":"ref66","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/annonc\/mdr265","article-title":"Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma","volume":"23","author":"A Gronchi","year":"2012","journal-title":"Ann Oncol"},{"issue":"44","key":"ref67","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/onc.2013.462","article-title":"Mode of action of trabectedin in myxoid liposarcomas","volume":"33","author":"S Di Giandomenico","year":"2014","journal-title":"Oncogene"},{"issue":"5","key":"ref68","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/0008-5472.CAN-09-3234","article-title":"Signal transduction networks in cancer: quantitative parameters influence network topology","volume":"70","author":"DJ Klinke","year":"2012","journal-title":"Cancer Res"},{"issue":"10","key":"ref69","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1101\/gr.101386.109","article-title":"Origins, evolution, and phenotypic impact of new genes","volume":"20","author":"H Kaessmann","year":"2010","journal-title":"Genome Res"},{"issue":"21","key":"ref70","doi-asserted-by":"crossref","first-page":"6312","DOI":"10.1093\/nar\/gkh972","article-title":"PreSPI: a domain combination based prediction system for protein-protein interaction","volume":"32","author":"DS Han","year":"2004","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"ref71","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1073\/pnas.0712255105","article-title":"Defining genetic interaction","volume":"105","author":"R Mani","year":"2008","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"ref72","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrd2355","article-title":"Utilizing RNA interference to enhance cancer drug discovery","volume":"6","author":"E Iorns","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"ref73","doi-asserted-by":"crossref","first-page":"e43305","DOI":"10.1371\/journal.pone.0043305","article-title":"TARGETgene: A Tool for Identification of Potential Therapeutic Targets in Cancer","volume":"7","author":"CC Wu","year":"2012","journal-title":"PLos ONE"},{"issue":"11","key":"ref74","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"AL Hopkins","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"2","key":"ref75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tig.2015.11.003","article-title":"Understanding the genetic mechanisms of cancer drug resistance using genomic approaches","volume":"32","author":"X Hu","year":"2016","journal-title":"Trends Genet"},{"issue":"2","key":"ref76","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd2683","article-title":"Mechanisms of drug combinations: interaction and network perspectives","volume":"8","author":"J Jia","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"D1","key":"ref77","doi-asserted-by":"crossref","first-page":"D369","DOI":"10.1093\/nar\/gkw1102","article-title":"The BioGRID interaction database: 2017 update","volume":"45","author":"A Chatr-Aryamontri","year":"2017","journal-title":"Nucleic Acids Res."}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1006266","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1006266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T12:26:21Z","timestamp":1540297581000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1006266"}},"subtitle":[],"editor":[{"given":"Marco","family":"Punta","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":77,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1006266","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1006266","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]}}}